The average takeout premium for a research-stage biotech is tracking at 100% this year, the latest data show.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.